Disease Domain | Count |
---|---|
Neoplasms | 9 |
Endocrinology and Metabolic Disease | 4 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 14 |
Chemical drugs | 2 |
Recombinant polypeptide | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SREBF1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism mTOR agonists |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date09 Apr 2024 |
Sponsor / Collaborator |
Start Date19 Feb 2024 |
Sponsor / Collaborator |
Start Date01 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MHY-450 | Colorectal Cancer More | Preclinical |
MHY2245 ( SIRT1 ) | Ovarian Cancer More | Preclinical |
MHY1485 ( mTOR ) | - | Preclinical |
MHY336 ( Top II ) | Prostatic Cancer More | Preclinical |
SREBF1 inhibitors(Pusan National University) ( SREBF1 ) | Metabolic dysfunction-associated steatotic liver disease More | Preclinical |